INTRODUCTION Technical Field
The field of this invention concerns the manipulation and expression of mammalian genes. Background
With the development of genetic engineering over the last two decades, including restriction enzymes, reverse tran scriptase, cloning, polymerase chain reaction, Sequencing, and monoclonal antibodies, there has been an extraordinary increase in the ability to isolate, identify and manipulate nucleic acid sequences. As a result of these capabilities, numerous genes and their transcriptional control elements have been identified and manipulated. The genes have been used for producing large amounts of a desired protein in heterologous hosts (bacterial and eukaryotic host cell sys tems).
In many cases, the process of obtaining coding sequences and eliciting their expression has been a long and arduous one. The identification of the coding sequence, either cDNA or genomic DNA, has frequently involved the construction of libraries, identification of fragments of the open reading frame, examining the flanking sequence, and the like. In mminmalian genes where introns are frequently encountered, in many instances, the coding region has been only a small fraction of the total nucleic acid associated with the gene. In other cases, pseudogenes or multi-membered gene families have obscured the ability to isolate a particular gene of interest. Nevertheless, as techniques have improved, there has been a continuous parade of successful identifications and isolation of genes of interest.
For many reasons, it may be desirable to manipulate the coding region or the transcriptional regulatory regions with out isolating the coding region or cloning the coding region on a fragment where the coding region is the primary sequence. These reasons may include ease of manipulation, development of different pathways for expression, or the like.
Also, in many situations, one is primarily interested in a source of the protein product. The cell type in the body which produces the product is frequently an inadequate source. There is, therefore, significant interest in developing alternative techniques for producing proteins of interest in culture, with cells which provide for economic and efficient production of the desired protein and, when possible, appro priate processing of the protein product.
Relevant Literature Mansour et al., Nature, 336:348-352 (1988) , describe a general strategy for targeting mutations to non-selectable genes. Weidle et al., Gene, 66:193-203, (1988) , describe amplification of tissue-type plasminogen activator with a DHFR gene and loss of amplification in the absence of selective pressure. Murnane and Yezzi, Somatic Cell and Molecular Genetics, 14:273-286, (1988) , describe transfor mation of a human cell line with an integrated selectable gene marker lacking a transcriptional promoter, with tandem duplication and amplification of the gene marker. Thomas and Capecchi, Cell, 503-512, (19871, describe site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Song et al., Proc. Natl. Acad. Sci. USA, 84:6820-6824, (1987) , describe homologous recombination in human cells by a two staged integration. Liskay et al., "Homologous Recombination Between Repeated Chromo somal Sequences in Mouse Cells," Cold Spring Harbor, Symp. Quant. Biol. 49:13-189, (1984) , describe integration of two different mutations of the same gene and homologous recombination between the mutant genes. Rubnitz and Sub ramani, Mol. and Cell. Biol. 4:2253 -2258 , (1984 , describe the minimum amount of homology required for homologous recombination in mammalian cells. Kim and Smithies, Nucl. Acids. Res. 16:8887-8903, (1988) , describe an assay for homologous recombination using the polymerase chain reaction. Burke, et al., Science 236:806-812 (1987) describe yeast artificial chromosomes (YACs) . See also, Garza, et al., Science 246:641-646 (1989) and Brownstein, et al. Science 244:1348 -1351 (1989 .
See also, U.S. application Ser. No. 432,069, filed Nov. 6, 1989 and Ser. Nos. 466,088, filed Jan. 12, 1990 and 610,515, filed Nov. 11, 1990 , which applications are incorporated herein by reference.
SUMMARY OF THE INVENTION
Expression of mammalian proteins is achieved by homologous recombination, where a DNA sequence is inte grated into the genome or large fragment thereof for enhanc ing the expression of the target gene. The modified sequence may then be transferred to a secondary host for expression. Where an amplifiable gene is integrated adjacent to the target gene, the target region may be amplified for enhanced expression.
Two different targets may be employed: homologous recombination in a host cell comprising the wild type target gene; or integration into a selected YAC(s) or YAC library and transfer of the target region to the expression host. When using a YAC or YAC genomic library containing mamma lian DNA, particularly human, the gene of interest is manipulated by homologous recombination, which includes the introduction of an amplifiable gene in proximity to the target gene to allow for amplification, and may in addition include, depending upon the expression host, modification of the transcriptional system, and modification(s) of the coding region. Depending upon whether the gene can be expressed in the yeast host, usually the YAC will be trans formed into a mammalian cell expression host for integra tion and expression of the target gene. Amplification can now be induced and cells selected for stable high levels of expression of the target protein.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
Methods and compositions are provided for production of mammalian proteins of interest in culture, particularly where one wishes to manipulate the native transcriptional system and/or coding region. The method employs integrating DNA by homologous recombination into genomic DNA, either in the native primary host cell or in a yeast primary host cell, 5,578,461 3 using YAC(s) or YAC genomic library as the source of the target gene. The former technique is described in patent application Ser. No. 432,069, filed Nov. 6, 1989. For transformation of the primary host cell, the cells may be grown and transformed with the DNA targeting construct, using any of a variety of Selection techniques for selecting cells having the proper integration. Usually, there will be only one or two integration steps. For the most part, the constructs and techniques employed will be the same for targeting a gene in a chromosome of a native cell or targeting a gene in a large genomic fragment in a YAC.
The YAC library is maintained and propagated in a yeast host and homologous recombination is then employed for integrating a DNA targeting construct, usually comprising an amplifiable gene for integration into a target region comprising the target gene, which target gene encodes the protein of interest, while also allowing for, in the same or separate step, manipulation of the transcriptional system and/or the coding region. The modified yeast cells may then be analyzed and sequences providing for the desired modi fications identified. The amplifiable region may then, as appropriate, be transformed into the expression host and the amplifiable region amplified. The YACs are prepared in accordance with conventional ways. Genomic DNA is cleaved enzymatically, mechani cally, or by other means to provide fragments which will usually have at least about 50 kbp, more usually at least about 100 kbp, conveniently at least about 200 kbp and usually not more than about 2,000 kbp, more usually not more than about 1,000 kbp. The genomic DNA is inserted into a YAC and then screened using appropriate probes for identifying the presence of the target gene. The presence of the YAC may be verified by a selective medium for the markers present on the YAC. Yeast cells containing a YAC or YAC library may be characterized by hybridization analy ses or by the polymerase chain reaction (PCR) using prim ers. The identified YAC(s) may then be used for manipula tion.
The YAC will normally be transferred from the original yeast host to a different yeast host which is convenient for manipulation. The new host will be a haploid or diploid strain having a plurality, usually at least 2, and may have 5 or more mutations in different genes which allow for selec tion by complementation. Total yeast, DNA from the origi nal yeast host may be transformed into yeast cells or spheroplasts yielding cells, which may serve as the hosts for the manipulations. The resulting transformants may be plated on selective media which selects against transfor mants lacking the complementation markers present on the YAC. Alternatively, one may transfer the YAC by a genetic cross. The recipient host for manipulation will normally be either a haploid or diploid host having a genetic defect which will be complemented by the genotype of the original yeast strain. If diploid, the recipient host is sporulated and ascospores are mixed with the original yeast host on an appropriate medium to allow mating. If a haploid and of opposite mating type to the original host strain, cells may be mated directly. Hybrid diploids are selected on selective media, where only cross-hybrids grow due to complemen tation between the non-allelic auxotrophic markers. Hybrids may then be sporulated and either random spores selected, for example, using expression of the heterozygous recessive drug-resistance marker, can l, to select for haploid meiotic products, or tetrads dissected using a micromanipulator. The meiotic products may then be analyzed genetically for the presence of the YAC markers, as well as the genetic markers present in the recipient strain. The presence of the YAC may be confirmed by hybridization or PCR analyses.
The manipulation of the mammalian DNA sequence in the YAC may be achieved in accordance with known techniques for homologous recombination in yeast. Thus, the sequence to be integrated into the mammalian sequence will have a region of homology of at least about 50 bp, more usually at least about 200 bp, usually. at least about 50 bp at one terminus of the sequence homologous with the recombina tion target region, more usually at least about 200 bp, and usually at least 5 bp at the other terminus. The greater 5,578,461 S homology will usually be at the 5'-terminus for the gene activation or 3' terminus for generating other modifications, such as protein fusions or modifications aimed at increasing mRNA stability. Preferably, there will be at least a total of 100 bp of homologous sequence, more preferably at least about 200 bp with at least about 50 bp at each terminus. The homologous sequence may be 1 kbp or more.
Various sequences having homology to the target region may be employed. In addition to using sequences unique to the target region one may also use sequences which are homologous to repetitive sequences found in the mammalian genome, such as the Aiu, LINE, THE, etc. sequence, where on the targeting construct such sequence may be present in one or multiple copies, usually not more than about 10 copics. Alternatively, one may utilize sequences from a YAC arm, such as prokaryotic sequences associated with the YAC arm, genetic markers on the YAC which are absent from the yeast genome, or the like. Where homologous vector arm sequences are employed, one or more kb of homology may be used.
The use of these alternative sequences is particularly helpful when only a small amount of 5'-untranslated region or N-terminal amino acid sequence about the target gene information is known. The 3'-terminus will generally have at least about 20 bp of homology.
Alternatively, one may have one region of homology followed by other sequences to be inserted and a telomere as the construct, (referred to as a half-YAC) where a cen tromere may or may not be present.
The sequence to be integrated into the mammalian sequence may be introduced into the primary host by any convenient means, which includes calcium precipitated DNA, spheroplast fusion, transformation, electroporation, biolistics, lipofection, microinjection, or other convenient means. Where an amplifiable gene is being employed, the amplifiable gene may serve as the selection marker for selecting hosts into which the amplifiable gene has been introduced. Alternatively, one may include with the ampli fiable gene another marker, such as a drug resistance marker, e.g. neomycin resistance (G418 in mammalian cells), hygro mycin in resistance etc., or an auxotrophy marker (HIS3, TRP1, LEU2, URA3, ADE2, LYS2, etc.) for use in yeast cells.
Depending upon the nature of the modification and asso ciated targeting coinstruct, various techniques may be employed for identifying targeted integration. Conveniently, the DNA may be digested with one or more restriction enzymes and the fragments probed with an appropriate DNA fragment which will identify the properly sized restriction fragment associated with integration.
Besides an amplifiable gene, other DNA sequences may be employed to enhance expression, either by themselves or in combination with the amplifiable gene. Thus, one may use different promoter sequences, enhancer sequences, or other sequence which will allow for enhanced levels of expression in the expression host. Thus, one may combine an enhancer from one source, a promoter region from another source, a 5'-noncoding region upstream from the initiation methion ine from the same or different source as the other sequences, and the like. One may provide for an intron in the non coding region with appropriate splice sites or for an alter native 3'-untranslated sequence or polyadenylation site. Depending upon the particular purpose of the modification, any of these sequences may be introduced, as desired.
Other modifications may also be included. With relatively small deletions, insertions, point mutations, and the like, A wide variety of mutations may be of interest, not only as to modifications in the coding sequence, but also in the preparation of fusion proteins where, the target gene may be retained intact or a portion of the target gene may be substituted with the integrating sequence. A number of fusion proteins have found interest, where a constant region from a member of the immunoglobulin superfamily, par ticularly antibodies, more particularly AIgG isotype, may be fused to the target protein. Alternatively, one may wish to introduce an enzyme, metallothionein, homing receptor, glycoside recognition site, phospholipid recognition site, or the like. In this manner, one may modify the target protein to provide for desirable characteristics which are not natu rally present with the target protein.
In carrying out one or multiple transformation steps, each Step may be carried out in substantially the same way, except that one may choose to use various techniques other than selection at one or both steps. Where selection is intended, the sequence to be integrated will have with it a marker gene, which allows for selection. The marker gene may conve niently be downstream from the target gene and may include resistance to a cytotoxic agent, e.g. antibiotics, heavy met als, or the like, resistance or susceptibility to HAT, gancy clovir, etc., complementation to an auxotrophic host, par ticularly by using an auxotrophic yeast as the host for the subject manipulations, or the like. The marker gene may also be on a separate DNA molecule, particularly with primary mammalian cells. Alternatively, one may screen the various transformants, due to the high efficiency of recombination in yeast, by using hybridization analysis, PCR, sequencing, or the like.
Yeast are particularly susceptible to homologous recom bination, with a high degree of efficiency. Thus, the subject methodology allows for modification of the target locus with a high success rate so that one or a plurality of homologous recombinations may be carried out to achieve any particular modeling of the transcriptional initiation system, the coding region, or other aspect of the sequence of interest, as well as introduction of other sequences in cis, e.g., amplifiable genes.
For homologous recombination, constructs will be pre pared where the amplifiable gene will be flanked, normally on both sides with DNA homologous with the DNA of the target region. Depending upon the nature of the integrating DNA and the purpose of the integration, the homologous DNA will generally be within 100 kb, usually 50 kb, preferably about 25 kb, of the transcribed region of the target gene, more preferably within 2kb of the target gene. Where modeling of the gene is intended, homology will usually be present proximal to the site of the mutation. By gene is intended the coding region and those sequences required for transcription of a mature mRNA. The homologous DNA may include the 5'-upstream region outside of the transcrip 5,578,461 7 tional regulatory region or comprising any enhancer Sequences, transcriptional initiation sequences, adjacent sequences, or the like. The homologous region may include a portion of the coding region, where the coding region may be comprised only of an open reading frame or combination of exons and introns. The homologous region may comprise all or a portion of an intron, where all or a portion of one or more exons may also be present. Alternatively, the homolo gous region may comprise the 3'-region, so as to comprise all or a portion of the transcriptional termination region, or the region 3' of this region. The homologous regions may extend over all or a portion of the target gene or be outside the target gene comprising all or a portion of the transcrip tional regulatory regions and/or the structural gene.
In the case of the amplifiable gene, the homologous sequence will be Joined to the amplifiable gene, proximally or distally. Usually a sequence other than the wild-type sequence normally associated with the target gene will be used to separate the homologous sequence from the ampli fiable gene on at least one side of the amplifiable gene. Some portion of the sequence may be the 5' or 3' sequence associated with the amplifiable gene, as a result of the manipulations associated with the amplifiable gene.
The integrating constructs may be prepared in accordance with conventional ways, where sequences may be synthe sized, isolated from natural sources, manipulated, cloned, ligated, subjected to in vitro mutagenesis, primer repair, or the like. At various stages, the joined sequences may be cloned, and analyzed by restriction analysis, sequencing, or the like. Usually during the preparation of a construct where various fragments are joined, the fragments, intermediate constructs and constructs will be carried on a cloning vector comprising a replication system functional in a prokaryotic host, e.g., E. coli, and a marker for selection, e.g., biocide resistance, complementation to an auxotrophic host, etc. Other functional sequences may also be present, such as polylinkers, for ease of introduction and excision of the construct or portions thereof, or the like. A large number of cloning vectors are available such as pBR322, the puC series, etc. These constructs may then be used for integration into the primary mammalian host or yeast containing YAC.
In the case of the primary mammalian host, a replicating vector may be used. Usually, such vector will have a viral replication system, such as SV40, bovine papilloma virus, adenovirus, or the like. The linear DNA sequence vector may also have a selectable marker for identifying transfected cells. Selectable markers include the neogene, allowing for selection with G418, the herpes the gene for selection with HAT medium, the gpt gene with mycophenolic acid, complementation of an auxotrophic host, etc.
The vector may or may not be capable of stable mainte nance in the host. Where the vector is capable of stable maintenance, the cells will be screened for homologous integration of the vector into the genome of the host, where various techniques for curing the cells may be employed. Where the vector is not capable of stable maintenance, for example, where a temperature sensitive replication system is employed, one may change the temperature from the per missive temperature to the non-permissive temperature, so that the cells may be cured of the vector. In this case, only those cells having integration of the construct comprising the amplifiable gene and, when present, the selectable marker, will be able to survive selection.
Where a selectable marker is present, one may select for the presence of the targeting construct by means of the selectable marker. Where the selectable marker is not 8 present, one may select for the presence of the construct by the amplifiable gene. For the neogene or the herpestle gene, one could employ a medium for growth of the transformants of about 0.1-1 mg/ml of G418 or may use HAT medium, respectively. Where DHFR is the amplifiable gene, the selective medium may include from about 0.01-0.5 uM of methotrexate or be deficient in glycine-hypoxanthine-thy midine and have dialysed serum (GHT media).
In carrying out the homologous recombination, the DNA will be introduced into the expression host. Techniques which may be used include calcium phosphate/DNA co precipitates, microinjection of DNA into the nucleus, elec troporation, yeast protoplast fusion with intact cells, trans fection, polycations, e.g., polybrene, polyornithine, etc., or the like. The DNA may be single or double stranded DNA, linear or circular. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology (1989) , Keown et al., Methods and Enzymology (1990) Vol. 185, pp. 527-537 and Mansour et al., Nature, 336:348-352, (1988) .
Upstream and/or downstream from the target region con struct may be a gene which provides for identification of whether a double crossover has occurred. For this purpose, the herpes simplex virus thymidine kinase gene may be employed since the presence of the thymidine kinase gene may be detected by the use of nucleoside analogs, such as acyclovir organcyclovir, for their cytotoxic effects on cells that contain or lack a functional HSV-tk gene. The absence of sensitivity to these nucleoside analogs indicates the absence of the thymidine kinase and, therefore, where homologous recombination has occurred, that a double crossover event has also occurred.
Once the target region has been modified and the presence of the appropriate modifications established using restriction analysis, Sequencing, hybridization, PCR etc., the manipu lated YAC may then be used directly or may be further manipulated to reduce its size, e.g., restriction digestion or targeted fragmentation with a repeated mammalian sequences.
It may be desirable to increase the number of copies of the YAC per yeast cell in order to increase the efficiency of the transfer into mammalian cells. One may use a YAC with its appropriate host strain that allows a multi-fold amplifi cation of the YAC. See, for example, Smith et al., PNAS (1990) 87:8242-8246 . The YAC may be manipulated, as appropriate, to provide for appropriate markers for intro duction of the construct into the amplifiable YAC. The amplifiable YAC, when amplified, may also find use to improve the efficiency of gene targeting and homologous recombination.
Various secondary mammalian expression hosts are avail able and may be employed. These hosts include CHO cells, particularly DHFR deficient cells, monkey. kidney cells, C127 mouse fibroblasts, 3T3 mouse cells, Vero cells, etc. In the case of amplification, desirably the hosts will have a negative background for the amplifiable gene or an ampli fiable gene which is substantially less responsive to the amplifying agent.
In the presence of a marker, the transformed cells are grown in selective medium containing, for the DHFR gene about 0.01-0.5 uM methotrexate or GHT media with dia lyzed serum and, where another marker is present, e.g., the neogene, the medium may contain from about 0.1-1 mg/ml G48. The resistant colonies are isolated and may then be analyzed for the presence of the construct in Juxtaposition to the target gene. This may be as a result of detection of 5,578,461 9 expression of the target gene product, where there will normally be a negative background for the target gene product, use of PCR, Southern hybridization, or the like.
The cells containing the amplifying construct are then expanded and subjected to selection and amplification with media containing progressively higher concentrations of the amplifying reagent, for example, 0.1-200 uM of methotr exate for the DHFR gene, and may be analyzed at each selection step for production of the target product. Expan sion will include at least duplication and may result in at least 5 copies, preferably 10 copies or more in a tandem relationship. Thus protein productions will be increased at least 1.5 fold from expression from a single copy, usually at least 3 fold, preferably at least 5 fold.
The various clones may then be screened for optimum stable production of the target product and these clones may then be expanded and used commercially for production in culture. In this manner, high yields of a product may be obtained, without the necessity of isolating the message and doing the various manipulations associated with genetic engineering or isolating the genomic gene, where very large genes can be a major research and development effort.
The following examples are offered by way of illustration and not by way of limitation. 1:327-341) as the template using oligonucleotide primer pairs 3 and 4, and 5 and 6, respectively, which incorporated BamHI, Xba, NheI and Sall sites at their respective ends. Second, an Sphl-EcoRI fragment containing the splice acceptor of the human Ol globin gene second exon (nucle otides +143 to +251) is inserted between the SphI and EcoRI sites. This Sphl-EcoRI fragment is synthesized by PCR with p7tSVoHP (Treisman et al., PNAS (1983) 80:7428-7432) as the template using oligonucleotide primers 7 and 8, which incorporated SphI and EcoRI sites at their respective ends. Third, the synthetic polylinker 5'-EcoRI-BgII-Apal-Aat I 3' is inserted between the EcoRI and the Aat sites. Fourth, a HindIII-SacI fragment containing the CMV IE enhancer/ promoter (nucleotides -674 to -19, Boshart et al., Cell (1985) 41:521-530) and a Saci-Sph fragment containing the CMV IE first exon/splice donor (nucleotides -19 to +170) are inserted by three-part ligation between the HindIII and SphI sites. The HindIII-SacI fragment is prepared by PCR with puCH.CMV (M. Calos, Stanford Univ.) as the template using oligonucleotide primers 9 and 10, which incorporated HindIII and SacI sites at their respective ends. The SacI-Sph fragment is chemically synthesized.
pMF-F is constructed by three successive fragment inser tions into pMF, which is created by inserting the synthetic polylinker 5'-NheI-Bsu36I-HindIII-SphI-NotI-3' into pSKII between the KpnI and SacI sites, with the loss of those sites. First, a NheI-Bsu36I fragment containing nucleotides -452 to -36 of the FSH-B gene (5' targeting region) is synthesized by PCR with DNA from the human diploid fibroblast line WI38 (ATCCCCL 75) as the substrate and the oligonucle otide primers 11 and 12 and cloned between the Nhe and Bsu36I sites. Second, an Sph-Not fragment containing nucleotides +100 to +850 of the FSH-B gene (3' targeting region) is synthesized as described above with primers 13 and 14 and cloned between the Sph and Not sites. Finally, an 840 bp HindIII-SphI cassette isolated from plK contain ing the CMV IE enhancer, promoter, first exon and splice donor is cloned between the HindIII and SphI sites. pYFT1 is constructed by inserting the 6.2 kb Bsu36I fragment of pTD-F into the unique Bsu36I site of pMF-F, with the transcriptional orientation of the elements within the Bsu36I fragment identical to the CMV IE enhancer/ promoter in pMF-F. YAC screening: Two yeast artificial chromosome (YAC) libraries are screened to identify YACs containing the human FSH-B locus. Each YAC library is generated in the haploid Saccharomyces cerevisiae host strain AB 1380 (MAT a ade2-1 (ochre) lys2-1 (ochre) triplura3 his5 canl-100 (ochre) using pYAC4 (Burke et al. Science (1987) 236:806-812) . The YAC contains two yeast selectable markers, TRP1 and URA3. Thus, the presence of a YAC in strain AB1380 is verified genetically by scoring for the presence of the wildtype TRP1 and URA alleles. The CEPHYAC library (Albertsen et al. 1990, PNAS 87: 4256-4260) , which con sists of -50,000 colonies with an average YAC insert size of 430 kb (-7 haploid genome equivalents), is screened by PCR. A total of 113 pools of DNA, each prepared from -386 yeast colonies, are screened with FSH-3 primers 11 and 12 (see above) which generate a 416 bp fragment. The Wash ington University YAC library (Brownstein et al., Science (1989 ) 244:1348 -1351 , which consists of ~60,000 colonies with an average YAC insert size of 250 kb (-5 haploid genome equivalents), is screened by hybridization to filters prepared from pulsed-field gels. The YAC colonies are arrayed in pools of -386 colonies, chromosomal DNA is prepared from each pool and the DNA is separated on pulsed-field gels. The 416 bp FHS-3 PCR product prepared with primers 11 and 12 is used as a hybridization probe. Yeast colony hybridization to filters prepared from indi vidual YAC colonies (Traver, Klapholz, Hyman and Davis Transfer of YAC-FSH-31 to a new host: All yeast genetic manipulations employ standard methodology essentially as described in Sherman, Fink and Hicks (1986, Laboratory Course Manual for Methods in Yeast Genetics). To effi ciently carry out homologous targeting of YAC-FSH-31, the YAC is transferred to a new haploid yeast host strain, YPH252 (MATo ade2-101 (ochre) lys2-801 (amber) ura3 52 trplAl his3A200 leu2A1) (Sikorski and Hieter 1989, Genetics 122:19-27 ). This host contains nonreverting alleles of ura3, trp 1, leu2 and his3; with the latter three being deletion alleles. Total yeast chromosomal DNA is prepared in agarose plugs using standard methodology (McCormick et al., Technique (1990) YPH252/YAC-FSH-B cells and dialyzed against 1 mM EDTA, 10 mM Tris-HCl pH 7.4 for 48 hours. 2x10 CHO DHFR-cells are plated 12 hr prior to transfection on 6 cm dishes in DME/F12 media supplemented with 10% fetal bovine serum, glycine, hypoxanthine and thymidine (non selective media). For transfection, 150 ul of 2xHeBS (280 mM NaCl, 50 mM Hepes pH7.1, 1.5 NaHPO) is added to 15ug of yeast genomic DNA in 150 ui of 0.27M CaCl. The precipitate is allowed to form at room temperature for 25 minutes, added to cells in the absence of media and incu bated for 20 minutes at room temperature, then topped off 5,578,461 13 with 3 ml of media and incubated at 37° C. Four hours later, the cells are washed twice with serum-free media, incubated with 15% glycerol in HeBS for 4 minutes at 37° C., washed again in serum-free media followed by growth in nonselec tive media for 48 hours. The transfected cells are then split 1:20 into selective media in (DME/F12 supplemented with 10% dialyzed fetal bovine serum) and fed every 3 days. Heterodimeric FSH is detected by pulse labeling of trans fected clones with S-methionine followed by immunopre cipitation of protein collected from the conditioned media and from cell lysates (Keene et al. 1989, JBC 264, 4769-4775) . Analysis on native and denaturing polyacryla mide gels reveals a protein product similar to highly purified human FSH. Biological activity of the expressed product is confirmed using the in vitro granulosa cell aromatase bio assay (Jia et. al., J. Clin. Endocrinol. Metab. (1986 ) 62:1243 -1249 Jia et. al., Endocrinology (1986) 119:1570-1577).
Activation of G-CSF analog expression
Construction of G-CSF targeting vectors: To activate the expression of the G-CSF gene, a YAC targeting vector (pYGTl) is constructed containing the following elements (5' to 3'): a 5' targeting region consisting of nucleotides -361 to -69 of the G-CSF gene (Nagata et al., EMBO.J. (1986) 5:575-581), a DHFR expression cassette, the yeast select able marker LEU2, the human CMV IE enhancer/promoter? splice donor, a human O-l globin gene splice acceptor, and a 3' targeting region consisting of nucleotides -60 to +167 of the G-CSF gene. This plasmid is derived from plasmids pTD-G and pMF-G. Plasmid pTD-G is constructed by two successive fragment insertions into pTD. First, the 1.95 kb PvuII-BamHI fragment of SV2DHFR encoding the SV40 early promoter, the DHFR gene, the SV40 t antigen intron and the SV40 early polyadenylation site is joined to Mul linkers and cloned into the Mlul site. Second, the 2.2 kb Sall-XhoI fragment of YEp13 encoding the yeast selectable marker LEU2 is cloned into the XhoI site. The order of these elements within the Bsu36 cassette was 5'-SV2DHFR pMF-G is constructed by the insertion into pMF of three fragments in two steps. First, an Nhe-Bsu-36I fragment containing nucleotides -361 to 69 of the human G-CSF gene (5' targeting region) is generated by PCR using oligonucle otide primers 17 and 18, and cloned between the Nhel and Bsu36I sites. Second, an EcoRINotI fragment containing nucleotides -60 to +167 of the G-CSF gene is generated by PCR using oligonucleotide primers 19 and 20. This EcoRI Not fragment and a HindIII-EcoRI fragment from pK containing the CMV IE enhancer/promoter/splice donor and human o-l globin splice acceptor, are inserted by three-part ligation between the HindIII and Not sites.
pYGT1 is constructed by inserting the 4.2 kb Bsu36I fragment of pTD-G into the unique Bsu36I site of pMF-G, with the transcriptional orientation of the elements within the Bsu36I fragment identical to the CMV enhancer/pro moter in pMF-G.
To create sequences capable of directing the modification of the G-CSF polypeptide, a YAC targeting vector (pYGT2) is constructed containing the following elements (5' to 3'): a 5' targeting region consisting of nucleotides +1180 to +1480 of the G-CSF gene, an IgG2 heavy chain cDNA encoding the hinge, CH2 and CH3 domains (amino acids 216-478, Kabat et a 1983, Sequences of Proteins of Immunological Interest), an SV40 early polyadenylation site, the yeast selectable marker HIS3, and a 3' targeting region consisting of nucleotides +1496 to +2599 of the G-CSF gene. The 5' targeting Sequences and IgG2 cDNA sequences are config ured such that upon Successful targeting a sequence encod ing a hybrid G-CSF-IgG2 protein would-be created in which Gln-176 of G-CSF is fused to Glu-216 of the IgG2 hinge region. pYGT2 is constructed by four successive fragment insertions into pDS, which is created by inserting the syn thetic polylinker 5'-Xbal-Mlul-BamHI-Sphl-SalI-3' into pSKII between the KpnI and SacI sites, with the loss of those sites. First, an Mlul-BamHI fragment containing the SV40 early polyadenylation site (nucleotides 2270 to 2533) is generated by PCR with pSV2DHFR as template using otigonucleotide primers 21 and 22 and inserted between the Mlul and BamHI sites. Second, the 1.7 kb BamHI fragment of pNN414 encoding the yeast selectable marker HIS3 (Traver et al, supra) is cloned into the BamHI site. Third, an Xbal to blunt-ended fragment containing nucleotides +1180 to +1480 of the G-CSF gene, and a blunt-ended to Mlul fragment encoding amino acids 216-478 of the IgG2 heavy chain are inserted in a three part ligation between the Xbal and Mlul sites. The G-CSF gene fragment is generated by PCR using oligonucleotide primers 23 and 24, and the IgG2 fragment is generated by PCR with a cDNA clone obtained from a human spleen cDNA library (Clontech) as template using oligonucleotide primers 25 and 26. Finally, a 1.1 kb Sphl-Sal fragment containing +1496 to +2599 of the G-CSF gene, generated by PCR using oligonucleotide prim ers 27 and 28 is inserted between the SphI and Sal sites. Gene targeting of the G-CSF locus Identification of a YAC colony containing the human G-CSF locus (YAC-G-CSF-1) using the 1.1 kb Sphi-SalI fragment as probe and transfer of the YAC to yeast strain YPH252 are carried out as described above for the FSH-B locus. To activate the expression of a GCS-F-IgG2 hybrid polypep tide, two successive gene targeting events are carried out using the targeting vectors pYGT1 and pYGT2. First, the targeting vector pYGT1 is digested with Nhe and Noti to liberate a 4.7 kb fragment. This fragment is used to trans form yeast spheroplasts of the strain YPH252/YAC-G-CSF 1. Total yeast genomic DNA from Leu-transformants is subjected to Southern blot analysis and compared with DNA from untransformed cells to detect targeting of the G-CSF locus. DNA is digested with restriction enzymes and probed with a -1.1 kb fragment from the 3' untranslated region of the G-CSF gene lying outside the targeted region. This probe is generated by PCR using oligonucleotide primers 27 and 28. Correctly targeted colonies display hybridizing frag ments consistent with the insertion of the ~4.7 kb corre sponding to SVDHFR, Leu2 and CMV IE sequences. Next, the targeting vector pYGT2 is digested with Xbal and SalI to liberate a ~4.1 kb fragment. This fragment is used to transform yeast spheroplasts of the strain created by the above targeting event. Total yeast genomic DNA from His--transformants is subjected to Southern blot analysis and compared with DNA from untransformed cells to detect targeting of the G-CSF locus. DNA is digested with restric tion enzymes and probed with a 300 bp fragment from the 5' untranslated region of the G-CSF gene lying outside the newly targeted region. This probe is generated by PCR using oligonucleotide primers 17 and 18. Correctly targeted colo nies display hybridizing fragments consistent with the inser tion of the -4.1 kb corresponding to IgG2, SV40 and HIS3 sequences. Total DNA is prepared from the doubly targeted yeast strain and used to transfect CHO DHFR cells as described above for the FSH-B gene. Following gene ampli fication of the transfected G-CSF-IgG2 sequences, CHO colonies are analyzed for expression of the G-CSF analog.
Analysis of YAC transfected CHO clones Secreted G-CSF-IgG2 is characterized by labeling trans fected clones with S-methionine followed by immunopre cipitation of culture supernatants and cell lysates as described (Capon et al., Nature (1989) 337:525-531) . Washed immunoprecipitates are eluted and electrophoresed on polyacrylamide gels under reducing conditions and visu alized by autoradiography to reveal the hybrid polypeptide.
The presence of the G-CSF moiety is confirmed by Western blot analysis. Unlabelled supernatants are similarly immunoprecipitated and electrophoresed and the proteins transferred to nitrocellulose filters (Burnette, Anal. Biochem (1981) 112:195) The filters are treated with a rabbit poly The following example describes the use of a mammalian primary host cell for the target DNA.
Isolation of a Genomic Clone Containing
Sequences for Targeting Erythropoietin A clone was obtained by Screening a human placental DNA genomic library (Clontech) in EMBL 3-SP6/T7 using two 36 bp oligonucleotide probes 5'-CTGGGTTGCT. (SEQ ID NO:37) designed to add Mlul sites at the ends of the resultant fragment. The neo and dhfr genes wwere cloned into the XhoI and Mlul sites respectively of pCG.CMV/EPO to give the plasmids pCG.CMV/EPO/ DHFR and pCC.CMV/EPO/Neo/DHFR such that their tran scription is in the same orientation as that of CMV. Finally, the 5 kb BamHI-HindIII fragment from pTD.1 was added via Clal adapters at the Clal site of pCG.CMV/EPO/Neo/ DHFR to give pCG.HR1. In pCG.HR1, the 5' 5 kb EPO fragment is in the same orientation as that of the 620 bp BstEII-Xbal fragment with respect to the original lambda clone.
A9.54 kb fragment containing the 5' 5 kb BamHI-HindIII EPO fragment, the dhfr and G418 markers, the CMV enhancer/promoter and the 620 bp BstEII-Xbal EPO frag ment can be released from pCG.HR1 as a NotI or SacII fragment. This Not I fragment can be used for homologous recombination as it is designed to serve as an omega structure in recombination having 5 kb and 620 bp of homology to facilitate the event.
For electroporation, the DNA was first cut with NotI, then extracted with phenol/chloroform and precipitated by the addition of ethanol before centrifugation. The resultant DNA pellet was resuspended at a concentration of 2 mg/ml in a volume (10 ul) of 10 mM Tris-Hcl, 1 mM EDTA (TE).
Introduction of DNA into cells
Transformed primary human 293 embryonal kidney cells (ATCC CRL 1573) were cultured in Cellgro DMEM H16 (Mediatech) supplemented with 10% calf serum, glutamine (2 mM) and penicillin (100U/mi)/streptomycin (0.1 mg/ml) and grown at 37° C. in 5% CO. At 90% confluency, cells were prepared for electroporation by trypsinization, concen tration by brief centrifugation and resuspension in PBS at 10 cells/0.8 ml. The cells were equilibrated at 4° C. and DNA (50 ug) restricted with Not (as described above) was added. The mixture was electroporated at 960 uf and 260 V with a BioRad Gene Pulser and then iced again for 10 min before plating onto a 10 cm dish. After incubation at 37° C. for 48 hr, the cells from a 10 cm dish were split equally among 5 24-well plates in media containing G418 at 0.6 mg/ml (effective Concentration). Under these electropora tion conditions, 4-10 colonies/well survive drug selection after 2 weeks.
Detection of Homologous Recombination by PCR Analysis
Using NotI restricted DNA from pCC.HR1, successful homologous recombination is obtained by insertion of the 3.8 kb construct at the targeted EPO locus while simulta neously deleting 1.2 kb of genomic sequence. PCR is used to detect unique targeting events versus-random integration of the DNA. Two primers are synthesized, one to the 3' end of CMV and the other to the region 3' to the Xbal site used for the 620 bp BstEII-Xbal fragment in the targeting DNA. A homologous recombination event generates a DNA target in the genome from which these primers produce an ampli fication product of 860 bp.
In order to detect the targeting event, pools of clones (from the electroporated 293 cells) from 4 wells each (representing about 16 colonies) were generated by trypsinizing wells and using 90% of each well for the pool. The remaining 10% of each well was then reseeded back into the well. Genomic DDNA was then prepared from each pool as follows. The cells in each pool were pelleted by centrifugation for 2 min. in a 1.5 ml microcentrifuge tube, resuspended in OBS (20 ul), and treated for 1 hr at 37° C. with a solution (400 l) containing 10 mM Tris-HCl (pH7.5), 100 mM. NaCl, 5 mM EDTA, 1% SDS and RNase A (40 g/ml). Proteinase K (10 ul, 10 g/ml) was then added, and the samples were incubated for 4 hr at 50° C. before extractions by vigorous vortexing with phenol/chloroform (200 ul each), then with chloroform (400 ul), the addition of ethanol (800 pull each), and centrifugation at 25°C. for 10 min. The DNA pellets were washed with 70% ethanol, dried Following an initial incubation of 94° C. for 3 min., the samples were subjected to 45 cycles of denaturation at 94° C. for 1 min., annealing at 66°C for 1.5 min. and extension at 72 C for 2 min. At the end of the 45 cycles, the samples were incubated an additional 5 min. at 72° C. A portion (20 ul) of each sample was analyzed on a 1% agarose gel run in TBE and stained with ethidium bromide. Out of the 90 pools analyzed from 3 electroporations, two samples were identified which exhibited the correct size fragment by ethidium bromide staining. The DNA from the PCR reaction was recovered and subjected to restriction mapping with Xbal. The correct amplification product should upon treatment with Xbal yield two fragments, 669bp and 191 bp. The samples from the two pools both yield fragments of the correct sizes. In addition, the sample from pool 1 exhibits other bands in the uncut material.
Following the procedure described previously, metaphase chromosomes are prepared from the recipients demonstrat ing homologous recombination with DHFR and transformed in DHFR deficient CHO cells. After isolating resistant colonies and analyzing for expression of EPO, the cell clones are grown in selective medium containing progres sively higher concentrations of methotrexate (0.02-80 uM) with steps of 4-fold increases in concentration. The ceils are then harvested, cloned and screened for production of EPO.
Clones providing for at least 2-fold enhancement of EPO production are isolated.
It is evident from the above results, that a simple accurate technique has been developed which allows for the ready manipulation of genes with high efficiency, introduction of amplifiable markers to allow for amplification of a target gene, modifications of genes, and transfer of the resulting modified chromosomal DNA to a mammalian expression host, to provide for efficient expression of the desired product having the same, substantially the same, or different composition from the natural product. Thus, one can obtain processing, combinations of products due to variation in splicing, processing, such as glycosylation, acetylation, methylation, or the like, as well as high and efficient levels of stable production of the desired product. Thus, a rapid, efficient methodology is provided for producing expression constructs for transformation into mammalian expression hosts, without the need for isolating and purifying the target gene and allowing for modification of the target gene with high efficiency. All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publi cation or patent application was specifically and individually indicated to be incorporated by reference.
The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.
